GlaxoSmithKline's RIPK1 inhibitor dead on arrival

Just one year ago, encouraging preclinical data saw GlaxoSmithKline kick-start a new clinical test of its investigational RIPK1 inhibitor GSK095. Now, the drug’s test in a tough-to-beat cancer has been axed.

A brief line from its third-quarter financials posted this morning read: “GSK095 for pancreatic cancer was terminated as part of ongoing portfolio prioritisation.”